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A common necessity for all papillomaviruses is to induce DNA synthesis in quiescent cells. This is commonly achieved by
the E7 gene product, which interferes with the function of members of the retinoblastoma family controlling transition from the
G1-phase to the S-phase of the cell cycle. Uncontrolled entry into S-phase activates, however, negative growth control signals
which have to be bypassed to achieve production of progeny viruses. In addition to inherent activities of the E7 protein, high
risk genital types encode an E6 protein that overcomes p53-mediated G1-arrest and apoptosis in concert with the cellular factor
E6AP by targeting p53 for the enhanced ubiquitin-dependent degradation. The key question, which of these functions of genital
E6 and E7 proteins is responsible for the carcinogenic phenotype, is still not completely answered. In contrast to high risk genital
types no immortalizing or transforming activities have been found for the E7 proteins of the high risk cutaneous HPV8 and 47.
On the other hand the ability of the E6 protein to transform established rodent fibroblasts seems to be a property shared by
high risk genital and cutaneous types. To examine the existence of a common E6-mediated transforming pathway for both virus
groups we compared the properties of the cutaneous E6 proteins with already known functions of E6 proteins of genital viruses.
For this we analyzed the E6 proteins of low risk and high risk cutaneous and genital papillomaviruses with respect to cell
transformation, to their abilities to bind, degradate, and influence the activity of human p53, and to bind E6AP. The results of
our study demonstrate a clear lack of interaction between the transforming E6 proteins of HPV1 and HPV8 and both cellular
proteins p53 and E6AP. In contrast, we found E6AP-independent binding of HPV16 E6 and HPV6 E6 to p53, although both
proteins were different in their transforming potential. Of all four proteins investigated, only HPV16 E6 was able to bind to p53
and E6AP and to induce degradation of the p53 protein in the reticulocyte system. When we investigated in frame deletion
mutants of the E6 protein of HPV16 for their abilities to bind to p53 or E6AP, degradate, and inhibit the transactivation function
of p53 and to transform rodent fibroblasts, no correlation between the different activities could be found. Mutants still able to
bind p53 and E6AP lacked transforming ability and other mutants that were transformation-competent were deficient in p53 and
E6AP binding. q 1997 Academic Press
INTRODUCTION related papillomaviruses also play a role in the origin of
skin cancers of immunosuppressed patients (Berkhout
The carcinogenic potential of papillomaviruses was
et al., 1995; Shamanin et al., 1996). Renal allograft recipi-
detected in 1935, when Rous and Beard (Rous and Beard,
ents that are at highly increased risk of developing squa-
1935) showed that inoculation of cottontail rabbit papillo-
mous cell carcinomas share surprising similarities with
mavirus (CRPV) into rabbits was sufficient to induce skin
EV-patients; e.g., in the stepwise progression from cuta-
carcinomas in these animals. The first human papillo-
neous warts through squamous epithelial atypia into in-
maviruses (HPV) shown to be involved in the develop-
vasive cancer, in the role of UV light as environmental
ment of malignancies represent a subgroup of cutaneous
cofactor, and in the presence of papillomavirus se-
HPV types specifically associated with the rare disease
quences in cancer biopsies (Pfister, 1992; Barr et al.,
epidermodysplasia verruciformis (EV). Patients with EV
1989; Hoxtell et al., 1977; Berkhout et al., 1995).
have an increased susceptibility to infections with vi-
Another large group of human papillomaviruses asso-
ruses of this subgroup. Certain high risk EV-types, like
ciated with human malignancies consists of more than
HPV5 and HPV8, are frequently detected in skin cancers 24 genital HPV types that are associated with lesions in
that develop from multiple flat warts in sun-exposed the anogenital tract (de Villiers, 1989). Distinct high risk
areas of the body in 30–60% of all EV patients (Pfister, types of this group are frequently detected in malignant
1992; Orth, 1987). More recent data suggest that EV- tumors, like HPV16 or HPV18, which are associated with
70% of all cervical carcinomas. The malignant phenotype
of genital high risk types seems to depend on the proper-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 07071-295790. E-mail: tsiftner@med.uni–tuebingen.de. ties of the gene products of both viral genes E6 and E7.
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This was first evident from studies with cervical carcino- late with the capacities of their E6 and E7 proteins to
induce cell proliferation (Huibregtse and Scheffner, 1994;mas in which almost all tumors revealed a continuous
expression of the E6/E7 region (zur Hausen, 1994; Smot- Vousden, 1991). The high risk genital HPV E7 proteins
were found to have a much higher affinity to the Rbkin and Wettstein, 1986; Schwarz et al., 1985). In addition
antisense RNA experiments with cultured cervical carci- protein than the low risk HPV E7 proteins (Heck et al.,
1992), and their transforming capacity parallels the Rbnoma cells showed that the expression of high risk E6
and E7 was necessary for growth potential and tumorige- binding activity. The E6 proteins of high risk HPV16 and
18 were shown to efficiently cause degradation of p53,nicity of the carcinoma cells (von Knebel Doeberitz et al.,
1992; Crook et al., 1989; von Knebel Doeberitz et al., whereas the ability of low risk HPV6 and 11 E6 proteins
to bind p53 in vitro is controversial, although they clearly1988). From a number of studies it soon became appar-
ent that the properties of E6 and E7 of high risk and low do not mediate degradation of p53 (Huibregtse and
Scheffner, 1994; Lechner and Laimins, 1994; Crook et al.,risk genital viruses in tissue culture correlated well with
the carcinogenic potential of the respective genital HPV 1991). As with Rb, the mechanism of induction of growth
arrest or apoptosis by wild-type p53 seems to be relatedtype (Huibregtse and Scheffner, 1994). The E7 gene of
the high risk genital HPV16 was found to be sufficient to to events at the transcriptional level (Jansen Du¨rr, 1996).
The p53 protein can bind directly to its recognition se-immortalize primary foreskin keratinocytes (Halbert et al.,
1991; Hudson et al., 1990), whereas the E7 protein of low quence on the DNA resulting in transcriptional activation
of a nearby located promotor (Barak et al., 1993; el Deiryrisk type HPV6, which is predominantely found in benign
genital warts revealed no immortalizing activity on its et al., 1993). In addition p53 can negatively regulate cer-
tain promoters in a sequence-independent way (Lechnerown (Halbert et al., 1992). High risk HPV16 E6 protein
induces anchorage-independent growth of C127 and NIH et al., 1992, and references therein).
All these data indicate that a number of different prop-3T3 cells, whereas the E6 proteins of the low risk genital
HPV types express no comparable cell-transforming ac- erties of the E6 and E7 proteins seem to be required for
the transformation of cells. Whereas the sole function oftivities (Barbosa et al., 1991).
Many other abilities of the E6 and E7 proteins of high E6 in the immortalization of human keratinocytes could
be to inactivate p53, this function may not be sufficientrisk genital types have been described till today, but a
key feature is certainly their ability to inactivate tumor for the transformation of rodent fibroblasts. To identify
new functions of the E6 protein besides the ability tosuppressor proteins. All papillomaviruses share the need
to induce DNA synthesis in quiescent host cells for the degradate p53, other cellular ligands were searched for.
One newly identified ligand of E6, termed E6BP, is areplication of the viral DNA. This is commonly achieved
by the interaction of the E7 protein with members of putative calcium binding protein (ERC-55) and interacted
with the E6 proteins of high risk genital types and withthe retinoblastoma tumor suppressor family, like p105Rb,
p107, and p130 (Schmitt et al., 1994; Gage et al., 1990; BPV1 E6 (Chen et al., 1995), but not with nontransforming
genital E6 proteins or with the transforming E6 proteinDavies et al., 1993; Dyson et al., 1989). Such unscheduled
DNA synthesis, however, leads to the induction of growth of CRPV (Harry and Wettstein, 1996). Recently the focal
adhesion protein paxillin was found to interact specifi-arrest or apoptosis in the infected cell. Additional proper-
ties of the E6 and E7 proteins are therefore required to cally only with transforming mutants of the BPV1 E6 pro-
tein and with the E6 proteins of high risk genital HPV16allow cells to proliferate even in the presence of negative
growth signals. In the case of HPV16, it was shown that but not with the low risk types 6 and 11. In the case of
BPV1 E6 this interaction correlated with the disruption ofE7 alone could bypass growth arrest signals mediated
by different pathways. An elegant mutational analysis the actin cytoskeleton in transformed rodent cells point-
ing to a role for this interaction for cell transformation byrevealed that yet unidentified functions in the E7 protein
besides Rb binding are necessary for the ability to abro- fibropapillomaviruses (Tong and Howley, 1997).
As compared to the genital papillomaviruses, only agate growth arrest. This property, however, correlated
well with the transforming potential of the different mu- small number of investigations has been performed on
the transforming potential of the E6 and E7 proteins oftants in rodent fibroblasts (Demers et al., 1996). One well-
characterized pathway for the induction of growth arrest cutaneous types. One interesting common feature of all
cutaneous high risk HPV types is that their oncogenicand apoptosis is by the activation of the p53 tumor sup-
pressor protein (Ko and Prives, 1996). In order to abro- potential mainly seems to rely on the activity of the E6
protein, but not on E7. Transforming potential could begate this cellular response some E6 proteins bind to p53
in concert with another cellular factor, E6AP, and target assigned only to the gene product of the E6 ORF, which
revealed transforming potential in rodent fibroblasts butp53 for the enhanced ubiquitin-dependent degradation
by the proteasome (Huibregtse and Scheffner, 1994). no immortalizing activities in human keratinocytes (Iftner
et al., 1988; Kiyono et al., 1989, 1992; Schmitt et al., 1994;Differences in the abilities of the oncoproteins from
distinct genital types to target cell cycle regulators corre- Pfister, 1992). Furthermore with the help of the rabbit
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model system we recently could show that increased and other mutants that were transformation-competent
were deficient in p53 and E6AP binding.expression of CRPV E6 in the proliferating epithelial cell
layers of domestic rabbits as compared to cottontail rab-
bits correlates with an enhanced progression of the skin MATERIALS AND METHODS
tumors (Zeltner et al., 1994). The E7 gene product of the
Plasmid constructionshigh risk EV-associated HPV8 and HPV47 did not exhibit
detectable transforming function and showed only re- Plasmids encoding fusion proteins between the DNA
duced Rb binding activity (Iftner et al., 1988, 1990; Schmitt binding domain (DBD) of GAL4 (amino acids 1–147) and
et al., 1994; Kiyono et al., 1989). In contrast, the E7 protein E6 were constructed by PCR amplification of the coding
of the low risk cutaneous HPV1 exhibited strong trans- sequences for E6 from plasmids pBR322/HPV1 (nt 101–
forming and high Rb binding activities, which makes a 524) (Danos et al., 1983), pBR322/HPV16 (nt 104–557)
correlation between the Rb binding affinity of the E7 pro- (Seedorf et al., 1985), pSVL86/7 (nt 206–660) (Iftner et
teins of cutaneous viruses and the carcinogenic potential al., 1990), and pHPV6a(wg) (nt 103–555) (de Villiers et
of the parental type highly unlikely (Schmitt et al., 1994). al., 1981). Expression vectors encoding fusion proteins
These data show that the only transforming protein of between the activation domain (AD) of GAL4 (amino
high risk EV-associated papillomaviruses known to date acids 768–881) and p53 or E6AP, respectively, were con-
is the E6 protein. The mechanism how E6 of cutaneous structed by PCR amplification of the coding sequences
types transforms rodent cells remains unknown. So far for p53 (nt 1–1179 of the wild-type p53 sequence) from
no interaction between cutaneous E6 proteins and the plasmids BSKSp53 (Zakut Houri et al., 1985) and pGEM4/
p53 protein has been described, although one potential p53(135) (Chiba et al., 1990), and for E6AP (nt 638–2596
problem of the only two studies suggesting a lack of of the E6AP sequence) from plasmid pGEM1/E6AP (Hui-
interaction between CRPV E6 and HPV8 E6 with p53 was bregtse et al., 1993a). To construct the N-terminal dele-
the usage of extracts from murine F9 cells as source tion mutant of p53, an ATG initiation codon was intro-
for the p53 protein (Steger and Pfister, 1992; Harry and duced in the 5* oligonucleotide that starts at amino acid
Wettstein, 1996). Species-specific differences between 101. To create the C-terminal deletion mutant of p53 the
p53 proteins from mice or man may influence the binding PCR reaction was carried out with a 3* oligonucleotide
ability of different E6 proteins to p53, as demonstrated by that contained a TAA stop codon immediately after amino
the inability of HPV18 E6 to bind to murine p53 (Scheffner, acid 326. All cloned amplification products were se-
1997). In addition both groups checked for neither degra- quenced following a standard protocol (Ausubel et al.,
dation of p53 nor for binding of the E6 proteins to E6AP. 1990). All oligonucleotide primers used for cloning con-
Although another study reported an inhibition of p53- tained additional restriction sites. PCR-amplified prod-
mediated transcriptional transactivation by HPV1 E6 un- ucts were cleaved with appropriate restriction enzymes
der highly artificial conditions, the authors failed to dem- and in the case of E6 inserted into the multiple cloning
onstrate an interaction between HPV1 E6 and p53 till site of the vector pAS2 (Harper et al., 1993) or in the case
today (Kiyono et al., 1994). In view of this conflicting data, of p53 and E6AP inserted in the multiple cloning site of
we were interested in directly comparing the properties pGAD 424 (Bartel et al., 1993). The resulting plasmids
of the E6 proteins of low risk and high risk cutaneous and encode the GAL4 DNA binding domain fused in frame
genital papillomaviruses by using different experimental with the E6 proteins and the GAL4 activation domain
systems with respect to cell transformation, to their abili- fused in frame with the proteins p53 and E6AP, respec-
ties to bind, degradate, and influence the activity of hu- tively. Constructs based on pAS2 contain additionally a
man p53 and to bind E6AP. The results of our study short nucleotide stretch of 27 nucleotides encoding the
demonstrate a clear lack of any interaction between the hemagglutinin epitope in frame between the coding se-
transforming E6 proteins of HPV1 and HPV8 and both quences of GAL4 and E6. For COS7 expression HPV16
cellular proteins p53 and E6AP. In contrast, we found E6wt-HA and 142/149-HA were subcloned into pEFcx
E6AP-independent binding of HPV16 E6 and HPV6 E6 to (Mizushima and Nagata, 1990). Constructs for in vitro
p53, although both proteins differed in their transforming transcription/translation were based on the pBS/ ex-
potential. Of all four proteins investigated, only HPV16 pression vector (Vector cloning systems).
E6 was able to bind to p53 and E6AP and to induce
degradation of the p53 protein in the reticulocyte system. PCR mutagenesis
When we investigated in frame deletion mutants of the
E6 protein of HPV16 for their abilities to bind p53 or In order to generate a DNA template usable for the
PCR mutagenesis the plasmid pGEM HPV16 E6/E7E6AP, degradate, and inhibit the transactivation function
of p53 and to transform rodent fibroblasts, no correlation (Bo¨hm et al., 1993) was amplified with the oligonucleo-
tides 16 E6-BamHI-1: 5*-90AA-AAG-GGA-TCC-GCA-ATG-between the different activities could be found. Mutants
still able to bind p53 and E6AP lacked transforming ability TTT-CAG-GAC-CCA-CAG121-3* and 16 E6-BamHI-tag-2:
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3*537GT-TCT-TGT-GCA-TCT-CTT-TGG-GTC-GAC556-ATG- AAA-GGT-ATA-CGA-C287-5*; aa 56 BglII-4: 5*-255GC-ATA-
GTA-TAT-AGA-GAG-ATC-TTT-CCA-TAT-GCT-G287-3* andGGT-ATG-CTA-CAA-GGT-CTA-ATG-CGA-ATC-TCC-
TAG-GGG-CAC-5*, using an annealing temperature of 16 E6-BamHI-tag-2. For 71/90 first BglII-site: 16 E6-
BamHI-1 and aa 71 BglII-3: 3*291CA-CTA-TTT-ACA-AAT-507C. By doing this the stop codon of the ORF encoding
16 E6 was removed and the sequence for the hemaggluti- TTC-AAA-GTC-TAG-AAT-TAA-TCA-CTC-ATA-TC333-5*;
aa 71 BglII -4: 5* - 291GT -GAT -AAA - TGT- TTA- AAG- TTT-nin epitope was added to the 3* end. In order to construct
five in frame deletion mutants of HPV16 E6, we chose CAG-ATC-TTA-ATT-AGT-GAG-TAT-AG333-3* and 16 E6-
BamHI-tag-2, second BglII-site: 16 E6-BamHI-1 and aathe method of site-directed mutagenesis with four con-
secutive rounds of PCR amplification. Two BglII sites 90 BglII-3: 3*-356CCT-TGT-TGT-AAT-CTT-CTC-TAG-ATC-
TTG-TTT-GGC-AAC391-5*; aa 90 BglII-4: 5*356GGA-ACA-were introduced in frame with the coding sequence of
HPV16 E6, cloned into pLXSN (Halbert et al., 1992), di- ACA-TTA-GAA-GAG-ATC-TAC-AAC-AAA-CCG-TTG391-
3* and 16 E6-BamHI-tag-2. For 108/126 first BglII-site: 16gested with BglII and religated to create each individual
mutant. All in frame deletion mutants were completely E6-BamHI-1 and aa 108 BglII-3: 3*408CC-ACA-TAA-TTG-
ACA-TTC-TAG-AGT-GAC-ACA-GGA-C440-5*; aa 108 BglII-sequenced in both directions with the help of an ABI
sequencer. Unless otherwise indicated in the oligonucle- 4: 5*408GG-TGT-ATT-AAC-TGT-AAG-ATC-TCA-CTG-TGT-
CCT-G440-3* and 16 E6-BamHI-tag-2, second BglII-site:otide sequence, the bold and underlined nucleotides rep-
resent the sequence for the BglII restriction enzyme. 16 E6-BamHI-1 and aa 126 BglII-3: 3*-460C-CTG-TTT-TTC-
GTT-TCT-TTC-TAG-AGA-TAT-TCC-CCA-GC495-5*; aa 126Numbers at the 5* and 3* end of each oligonucleotide
refer to the nucleotide position in the HPV16 E6 wt se- BglII-4: 5*460-G-GAC-AAA-AAG-CAA-AGA-AAG-ATC-TCT-
ATA-AGG-GGT-CG495-3* and 16 E6-BamHI-tag-2. For 142/quence. The construction of the in frame deletion mu-
tants is exemplarily described for 18/25. To create the 149 first BglII-site: 16 E6-BamHI-1 and aa 142 BglII-3:
3*514C-AGA-ACA-ACG-CTC-TAG-AGT-TCT-TGT-GCA-first BglII-site HPV16 E6wt-HA was used as a template
in two parallel PCR reactions in which 16 E6-BamHI-1 TC543-5*; aa 142 BglII-4: 5*514G-TCT-TGT-TGC-GAG-A-
TCTCA-AGA-ACA-CGT-AG543-3* and BamHI-p2-pLXSN:and aa 18 BglII-3: 3*-140GGT-GTC-AAT-ACG-GTC-TAG-
AAG-GTT-TGT-TGA-TAT-G173-5* were used as oligonu- 3*CTC-CTA-GGC-CGA-CAC-CTT-ACA-C-5*, second BglII
site: 16 E6-BamHI-1 and aa 149 BglII-3: 3*537GT-GCA-cleotides in one reaction and aa 18 BglII-4: 5*-140
CCA-CAG-TTA-TGC-CAG-ATC-TTC-CAA-ACA-ACT-ATA- TCT-CTT-GTC-TAG-AAC-ATG-GGT-ATG565-5*; aa 149
BglII-4: 5*537CA-CGT-AGA-GAA-CAG-ATC-TTG-TAC-CCA-C173-3* and 16 E6-BamHI-tag-2 were used in the other
reaction. The resulting PCR products were gel purified TAC565-3* and BamHI-p2-pLXSN.
and used as templates in equal amounts for the second
Softagar assaysPCR amplification where 16 E6-BamHI-1 and 16 E6-
BamHI-tag-2 were used as primer. The resulting DNA-
Transfection of NIH 3T3 rodent fibroblasts, selection
fragment was used as a template for the introduction of
procedure by G418 and softagar assays were performed
a second BglII-site using the oligonucleotides 16 E6-
as described previously (Iftner et al., 1988; Schmitt et al.,
BamHI-1 and aa 25 BglII-3: 3*-165GT-TGA-TAT-GTA-TTC- 1994).
TAG-AAT-AAT-CTT-ACA-CAC-ATG-ACG202-5* as well as
aa 25 BglII-4: 5*165CA-ACT-ATA-CAT-AAG-ATC-TTA-TTA- Expression of the GAL4 fusion proteins in yeast
GAA-TGT-GTG-TAC-TGC202-3* and 16 E6-BamHI-tag-2 in
two parallel PCR reactions. The PCR products were gel Yeast strain Y190 (His0, Leu0, and Trp0; Harper et al.,
1993) was transfected simultaneously with 2 mg of apurified and used as templates in equal amounts for the
fourth PCR amplification step, where the same primer pAS2-derived plasmid (DBD of GAL4) as well as 2 mg of
a pGAD424-based plasmid (AD of GAL4) by a modifiedpair as in step two was used. The resulting PCR product
was cloned into the eukaryotic expression vector pLXSN lithium-acetate method as described previously (Soni et
al., 1993). Transfectants were allowed to grow on syn-via the two BamHI restriction sites incorporated in the
outer primer pair 16 E6-BamHI-1 and 16 E6-BamHI-tag- thetic media (SD), lacking the amino acids histidine, leu-
cine, and tryptophan for 4 days (Sherman et al., 1986),2. The construct was digested with the restriction enzyme
BglII and religated to obtain the in frame deletion mutant but containing 15 mM 3-amino-1,2,4-triazole (Sigma,
Mu¨nchen) to suppress leaky expression of the HIS3 gene18/25. Four more in frame deletion mutants were made
as described above with the help of the following oligo- (Durfee et al., 1993; Harper et al., 1993). For blue white
screening Leu/, Trp/ transfectants were soaked in chlo-nucleotides: for 35/56 first BglII-site: 16 E6-BamHI-1 and
aa 35 BglII-3: 3*192CA-CAC-ATG-ACG-TTC-TAG-AAC- roform, dryed, and overlaid with 1% low melting agarose
(FMC Bioproducts) containing 1 mg/ml X-Gal (Roth, Ger-AAT-GAC-GCT-GC222-5*; aa 35 BglII-4: 5*-192GT-GTG-
TAC-TGC-AAG-ATC-TTG-TTA-CTG-CGA-CG222-3* and 16 many), 100 mM KPO4 , and incubated at 307C for 24 h.
Colonies which turned blue due to b-galactosidase ex-E6-BamHI-tag-2, second BglII-site: 16 E6-BamHI-1 and
aa 56 BglII-3: 3*-255CG-TAT-CAT-ATA-TCT-CTC-TAG- pression were picked and transferred to a fresh SD-Leu
0-
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Trp0-plate. Liquid b-galactosidase assays were per- All other transient transfection experiments were per-
formed in the HPV negative cervical carcinoma cell lineformed with mid-log phase cultures by measuring the
release of o-nitrophenol from the substrate o-nitrophenyl- C33A (ATCC, MD). Then 1 mg CAT reporter (PG13CAT)
(Kern et al., 1992), 10 ng p53 wild-type expression con-b-D-galactopyranoside (ONPG, Sigma, Mu¨nchen). The
results are expressed as units defined by Miller (1972). struct (pC53SN3) (Baker et al., 1990), and expression
vectors for the E6 proteins of HPV1, 6, 8, or 16 (SchmittAt least five independent transfectants were analyzed for
each pair of constructs and each assay was performed et al., 1994) in various concentrations were cotransfected
in C33A cells (Iftner et al., 1988). Always 10 mg of theseveral times.
expression constructs for the mutant 16 E6 proteins were
Western blot and immunoprecipitation transfected. The concentration of DNA in each transfec-
tion was kept constant by the addition of parental expres-For Western blotting yeast clones cotransfected with
GAL4-DBD-E6 and GAL4-AD-p53 were grown in 5 ml SD sion vector DNA to a total of 20 mg. CAT assays were
performed for 3 h according to a standard protocol (Ausu-medium and harvested at an OD600  0.7. Cells were
quickly chilled on ice, centrifugated, and resuspended in bel et al., 1990) with 150 mg of protein extract to keep the
chloramphenicol-conversion rate within the linear range.500 ml of cold IP-buffer (1% Triton-X 100; 0.2% SDS; 0.3%
desoxycholate; 50 mM NaCl; 5 mM EDTA; 50 mM Tris – Acetylated and nonacetylated products were separated
by thin-layer chromatography. The percentage of acetyla-HCl at pH 8.0), containing 1 mM of the protease inhibi-
tors PMSF and leupeptin, aprotinin, chymostatin, and tion was determined by quantification of acetylated and
nonacetylated [14C]chloramphenicol with the help of apepstatin at a concentration of 2 mg/ml. Cells were lysed
with glass beads and six pulses of vortexing for 30 s phosphoimager (Bas 2000, Fuji).
separated by 30s incubations on ice. An additional 500-
ml aliquot of IP-buffer was added and the extract was In vitro transcription/translation and degradation
assaysclarified by centrifugation. Then 100 ml of the protein
extract was mixed with an equal amount of standard
For the expression of human wild-type p53 and HA-sample buffer (Maniatis et al., 1989) and proteins were
tagged HPV E6 proteins, we used T3 or T7 RNA polymer-separated by 15% SDS–polyacrylamide gel electrophore-
ase and a combined in vitro transcription/translation sys-sis (SDS–PAGE). Western blotting was performed by
tem (TNT rabbit reticulocyte lysate or TNT wheat germstandard technique as described previously (Coligan et
extract, Promega). To generate radioactively labeled pro-al., 1994). For detection of the GAL4-DBD-E6 fusion pro-
teins, translations were performed in the presence ofteins a monoclonal antibody specific for hemagglutinin
[35S]methionine/cysteine translabel (Amersham). Degra-(HISS Diagnostics, Freiburg) was used. Fusion proteins
dation assays were performed as described previouslycontaining p53 were detected with the monoclonal anti-
(Scheffner et al., 1990). For ubiquitination assays up tobodies PAb 421 (Dianova, Hamburg, Germany) and PAb
2 mM nonhydrolyzable ATPgS was added to the reaction1801 (St. Cruz, Munich, Germany). Proteins were visual-
mixture. Proteins were separated on 15% SDS–PAGEized by ECL Western blotting System (Amersham). For
and visualized by fluorography.immunoprecipitation, the pellet of 10 ml of a liquid yeast
culture (OD600  0.5) was resuspended in 300 ml of SD
RESULTSmedium lacking methionine. Then 500 mCi [35S]-
methionine/cysteine translabel (Amersham) was added Transforming properties of genital and cutaneous
for 5 min at 307C. Labeled yeast cells were chased with HPV E6 proteins
200 ml methionine (4 mg/ml). Cell extracts were prepared
as described above. Immunoprecipitations were per- To directly compare the transforming abilities of low
and high risk cutaneous versus genital papillomavirusesformed with the same antibodies as described for West-
ern blotting, using a protocol which was described pre- we investigated the transforming potential of the E6 pro-
teins of HPV1, 6, 8, and 16 in NIH 3T3 rodent fibroblastsviously (Iftner et al., 1990), with the inclusion of two further
washing steps of the beads in 15 ml 1% SDS (in IP- with the help of a semiquantitative softagar assay. Two
weeks after transfection G418-resistant colonies werebuffer) to reduce the background. Metabolic labeling and
immunoprecipitations of transfected COS7 cells were pooled and seeded in 0.3% agarose. Growing clones
consisting of more than 16 cells were identified andperformed as described previously (Iftner et al., 1990;
Gage et al., 1990). Quantification of signals was done by counted after 2 to 3 weeks. The E6 proteins of cutaneous
high risk type 8 and low risk type 1 were found to beusing a phosphoimager (Bas 2000, Fuji).
almost equally efficient in inducing anchorage-indepen-
Cell culture, transfections, and CAT assays dent growth of NIH 3T3 cells as the E6 protein of genital
high risk type 16. In contrast the number of coloniesCOS7 cells (CRL 1651; ATCC, MD) were grown and
transfected as described previously (Iftner et al., 1990). found with low risk HPV6 E6 protein was not significantly
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different from G418-resistant clones established by
transfection with the parental pZipNeoSV(X)-1 (Cepko et
al., 1984) expression vector (Fig. 1A). Therefore a signifi-
cant difference between high versus low risk cutaneous
E6 proteins in terms of transforming potential, as it is
known from the genital group, does not seem to exist.
Cutaneous E6 proteins do not induce ubiquitination or
degradation of p53
To abrogate one negative growth signal after unsched-
uled induction of DNA synthesis the E6 protein of HPV16
targets p53 and leads to its enhanced degradation
(Scheffner et al., 1990; Huibregtse et al., 1993a). To inves-
tigate such a direct effect on the p53 protein, we first
performed in vitro ubiquitination and degradation assays
with the cutaneous E6 proteins. For this, p53 was trans-
lated in the reticulocyte lysate system in the presence
of [35S]methionine/cysteine and incubated with in vitro-
translated E6 proteins of HPV1, 6, 8, and 16 at 257C.
Increasing amounts of nonhydrolyzeable ATPgS, which
blocks the energy-dependent degradation of p53 (Scheff-
ner et al., 1990), were added and the reactions were
stopped after 1 h. The total reaction mixtures were ana-
lyzed on SDS–PAGE and the p53 proteins were visual-
ized by fluorography. Even in the presence of 2 mM
ATPgS neither HPV1 E6 nor HPV8 E6 mediated ubiquiti-
nation of p53 in contrast to the positive control HPV16
E6 (Fig. 1B). As a negative control we used p53 in the
presence or absence of 2 mM ATPgS. Since we detected
no influence of the cutaneous E6 proteins on the stability
of p53 within 60 min of incubation time we next per-
formed a time course experiment to determine if longer
incubation periods would allow degradation of the tumor
suppressor protein. As shown in Fig. 1C in the absence
FIG. 1. The transforming E6 proteins of the cutaneous HPV types 1of E6 protein p53 is stable at least for 180 min. When in
and 8 do not degradate p53 in vitro. (A) Anchorage-independent growth
vitro-translated high risk HPV16 E6 protein is added, a of NIH 3T3 cells transfected with different E6 expression vectors. The
time-dependent degradation of p53 could be observed, cloning efficiency is given as the percentage [%] of seeded cells that
formed colonies of more than 16 cells after 2 to 3 weeks. Each barwith 96% of the input p53 protein degradated after 60
represents the average value of six individual experiments, while eachmin. As described earlier by other groups no degradation
experiment consisted of two independent transfections. Standard devi-could be observed with HPV6 E6 (Crook et al., 1991,
ations are depicted as black lines. (B) p53 and various E6 proteins
and data not shown). Similarly, incubation with the E6 were translated in vitro in rabbit reticulocyte lysate in the presence of
proteins of HPV1 or 8 (Fig. 1C) caused no degradation, [35S]methionine/cysteine. Ubiquitination reactions were performed in
the presence of increasing amounts of the nonhydrolyzable ATP analogthereby indicating that the cutaneous E6 proteins do not
ATPgS, as indicated. p53 and the high molecular weight ubiquitinatedmediate ubiquitin-dependent degradation of p53.
forms of p53 (p53*) are marked on the left. (C) Time course experiment
of E6 induced degradation of p53. p53 was incubated in the absence
Binding of the E6 proteins to p53 in the yeast two- or in the presence of equal amounts of either HPV16 E6, HPV1 E6, or
hybrid system HPV8 E6 at 257C as described under Materials and Methods. The
reactions were stopped at different time points and analyzed by SDS–
Although it is clear from the current data that the E6 PAGE followed by fluorography. The arrows at the right indicate the
proteins of low risk genital HPV6 and 11 do not mediate position of p53.
the degradation of p53, some groups reported binding
of the low risk E6 proteins to the tumor suppressor mole-
cule (Crook et al., 1991; Lechner and Laimins, 1994). In DNA binding ability of p53 (Lechner and Laimins, 1994;
Lechner et al., 1992). As far as cutaneous E6 proteinsaddition binding of HPV11 E6 to p53 was shown to influ-
ence the transrepressor function and sequence specific are concerned the results of our experiments did not
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indicate any interaction with p53. However, our in vitro together with GAL4-AD-p53 showed a clear activation of
the reporter gene lacZ, but the 16 E6 protein was twofoldassays only allowed the detection of prominent activities
and would not allow the identification of weak protein – more efficient. As far as the cutaneous E6 proteins of
HPV1 and HPV8 are concerned there was no activationprotein interactions, which still could be of biological
significance. To be able to investigate such possible of the reportergene lacZ when p53 was coexpressed
(Fig. 2A). These data show that the yeast two-hybrid sys-weak interactions of the cutaneous E6 proteins with p53
we used the yeast two-hybrid system (Fields and Song, tem allows measurement of direct interactions between
the E6 proteins of HPV6 or 16 and p53 even in the ab-1989). Yeast cells do not contain gene products similar
to the human E6AP protein (Goffeau et al., 1996), which sence of E6AP.
was shown in reticulocyte lysates to mediate the interac-
tion between HPV16 E6 and p53. Therefore any interac- Detection of E6 and p53 proteins in transfected yeast
tion between E6 and p53 found with the yeast two-hybrid cells
system should represent an E6AP-independent event.
First the E6 genes of HPV1, HPV8, HPV6, and HPV16 Since we did not detect any interaction between the
E6 proteins of HPV1 or HPV8 and human p53 when fusedwere cloned in frame into the vector pAS2 (Harper et al.,
1993) to produce fusion proteins with the aminoterminal to the functional domains of GAL4, we performed West-
ern blotting analysis to confirm the presence and stabilityDNA binding domain of the GAL4 transcription factor
(DBD; aa 1–147). As counterpart the coding sequence of the proteins in the transfected yeast clones. Protein
extracts from yeast clones cotransfected with GAL4-of human wild-type p53 protein (p53wt) was cloned in
frame into the vector pGAD424 (Bartel et al., 1993) to DBD-E6 and GAL4-AD-p53 were run on SDS–polyacryl-
amide gels, transferred to nitrocellulose filters, and incu-produce a fusion protein with the GAL4 carboxyterminal
transactivation domain (AD; aa 768–881). To be able to bated with a monoclonal antibody directed against the
hemagglutinin (HA) epitope that is present in all GAL4-select for transfected yeast cells, the vector pAS2 con-
tains the nutritional selection marker tryptophan and DBD-E6 fusion proteins (Fig. 2B, left panel). As negative
control we used extracts of mock-transfected Y190 cellspGAD424 encodes the marker leucine. Any interaction
between the fusion proteins produced by these vectors (Fig. 2B, mock). The GAL4-DBD-E6 proteins were visual-
ized using the ECL detection system (Amersham). Thiscan be directly measured by the activation of the two
GAL4-dependent reporter genes HIS3 and lacZ present analysis demonstrated the presence of all E6 fusion pro-
teins in the protein extracts from yeast clones cotrans-in the yeast strain Y190 (Harper et al., 1993). As negative
controls we transfected Y190 cells with GAL4-DBD-1 E6, fected with human p53. In parallel, the GAL4-AD-p53 pro-
tein was visualized by using the p53-specific monoclonal-8 E6, -6 E6, -16 E6, and GAL4-AD or cotransfected GAL4-
DBD with GAL4-AD-p53 to prove that activation of the antibody PAb 421 (Fig. 2B, right panel). In Fig. 2B (last
lane) the amount of GAL4-AD-p53 protein in cells con-reporter genes was only due to the interaction of fusion
proteins and not to the activity of a single compound. taining GAL4-DBD-8 E6 tends to be somewhat reduced;
however, this effect was not reproducible. In summaryCotransfection of yeast cells of strain Y190 with the
expression vectors GAL4-DBD-16 E6 or GAL4-DBD-6 E6 these data clearly show that the inability of cutaneous
E6 proteins to interact with p53 is not simply due totogether with GAL4-AD-p53 resulted in an activation of
the reporter gene HIS3, which could be detected by insufficient protein amounts.
To verify the interactions in yeast cells found by indi-growth of the yeast colonies on synthetic media lacking
histidine. Cotransfectants with GAL4-DBD-1 E6 or -8 E6 rect reporter assays between p53 and E6 we next per-
formed coimmunoprecipitation experiments with proteinand GAL4-AD-p53 did not result in colony formation on
media lacking histidine (data not shown). In a next step extracts from yeast clones cotransfected with GAL4-AD-
p53 and the different GAL4-DBD-E6 constructs. For this,all cotransfectants were tested for the expression of the
second independent reporter gene lacZ. For this trans- the respective Y190 clones were labeled with [35S]-
methionine/cysteine and protein extracts were preparedfected Y190 cells were grown on synthetic media sup-
plied with histidine but lacking the two selection markers using IP-buffer. When we performed immunoprecipita-
tions using the p53-specific monoclonal antibody PAbleucine and tryptophan. Five individual clones from each
transfection experiment were tested for b-galactosidase 421 we obtained a clear coprecipitation of the GAL4-
DBD-E6 protein only with cell extracts from Y190 cellsactivity. A quantitative test was performed to measure
the enzyme activity in units as defined by Miller (1972). cotransfected with GAL4-DBD-16 E6 (Fig. 2C, lane 1).
Extracts from Y190 cells cotransfected with the expres-The values given in Fig. 2A were referred to the activity
of Y190 cells cotransfected with the parental vectors, sion vectors GAL4-DBD-1 E6 and -8 E6 failed to coprecip-
itate the E6 proteins together with GAL4-AD-p53 (Fig. 2C,encoding the DBD and AD of GAL4, which was set to
the value ‘‘1.’’ lanes 3 and 4). Vice versa, when we used an HA-epitope-
specific antibody we observed coprecipitation of GAL4-Cotransfectants containing GAL4-DBD-6 E6 or -16 E6
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AD-p53 in Y190 cells cotransfected with GAL4-DBD-16
E6 (Fig. 2C, lane 9).
Characterization of the p53 protein domain
responsible for E6 interaction in yeast cells
While some groups already reported a direct E6AP-
independent interaction between genital E6 proteins and
p53 in vitro (Lechner and Laimins, 1994; Li and Coffino,
1996), we were interested which domain of p53 mediates
interaction with HPV6 and 16 E6 in the more physiologi-
cal milieu of yeast cells. For this we constructed different
expression vectors that allow the expression of GAL4-
AD-p53 fusion proteins with deletions at the aminotermi-
nal (p53ATG101) and carboxyterminal (p53Stop326) ends
of p53 or with an amino acid exchange within the p53
core region at aa position 135 (Cys-135-Tyr) (Chiba et
al., 1990). Y190 cells were cotransfected with the p53
mutant constructs and either expression vectors for
GAL4-DBD-E6 or -16 E6 and grown in selective media.
Five positive colonies were next tested for expression of
the second independent reporter gene lacZ in a quantita-
tive b-galactosidase assay (Fig. 3). Again a clear interac-
tion could be found between the GAL4-DBD-E6 fusion
proteins of HPV6 and 16 with the wild-type GAL4-AD-
p53 protein. While GAL4-DBD-16 E6, showing a three- to
fourfold stronger binding to GAL4-AD-p53 wild type, was
still able to interact with a C-terminal deletion mutant of
p53 (GAL4-AD-p53Stop326); the GAL4-DBD-E6 protein of
HPV6 lacked this ability. The N-terminal deletion mutant
(GAL4-DBD-p53ATG101) and the core mutant of GAL4-
AD-p53 (Cys-135-Tyr) did not interact with each of the
E6 proteins. This clearly shows that the aminoterminus
and the core region of p53 are essential for E6 binding.
In addition the results obtained with the carboxyterminal
mutant of p53 suggest an influence of this domain on
the strength of the protein–protein interaction. However,
it is clear that none of the p53 domains by themselves
were able to mediate interaction with E6. The difference
FIG. 2. Interaction between HPV E6 and p53 in yeast cells. (A) Y190
cells were cotransfected with GAL4-DBD-E6 fusion protein expression and the different E6 proteins were detected with a monoclonal antibody
vectors and with an expression vector for the GAL4-AD fused to human against hemagglutinin. Right panel: Fusion proteins consisting of the
p53 (dark bars). Transfected yeast clones were grown on synthetic GAL4-AD and p53 were detected with the p53 specific antibody PAb
media supplied with histidine but lacking the two selection markers 421. The second lane (0) represents yeast cells transfected with GAL4-
leucine and tryptophan. As negative controls served cotransfections of AD-p53 alone. The mock-transfected control cells harbor the GAL4
the respective expression vectors with either parental vector construct transcription factor. The positions of the molecular weight markers (in
(GAL4-DBD / GAL4-AD-p53, GAL4-DBD-8 E6 / GAL4-AD, GAL4-DBD- kDa) are shown on the left. (C) Y190 cells were grown in the presence of
1 E6 / GAL4-AD, GAL4-DBD-16 E6 / GAL4-AD, and GAL4-DBD-6 E6 [35S]methionine/cysteine before protein extracts were prepared. Yeast
/ GAL4-AD). The interaction between SV40 large T and p53 as well cells were transfected with GAL4-AD-p53 (lane 2) and DBD-1E6 (lane
as the activity of the full-length GAL4 transcription factor served as 3), DBD-8E6 (lane 4), or DBD-16E6 (lane 1). The p53-specific antibody
positive controls. All values were referred to the b-galactosidase activ- PAb 421 was used and the position of GAL4-AD-p53 and GAL4-DBD-
ity of Y190 cells cotransfected with the parental expression vectors 16 E6 are indicated with an arrow. In lane 9 the same extract as in
(GAL4-DBD / GAL4-AD) whose values were set to ‘‘1.’’ Standard devia- lane 1 was used, but incubated with an HA-specific antibody. Negative
tions are depicted as black lines. (B) For Western blotting extracts of controls are precipitations of transfected cells incubated with unrelated
cotransfected yeast cells were separated on 15% SDS–PAGE and blot- antibodies (lane 5 and 8) or extracts of untransfected (lane 6 and 10)
ted onto nitrocellulose filter membrane. Left panel: Fusion proteins as well as mock-transfected yeast cells (lane 7 and 11) precipitated
consisting of the GAL4-DBD, a hemagglutinin epitope of 9 aa length with specific antibodies.
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FIG. 3. Interaction between genital HPV E6 proteins and mutant p53 proteins in yeast cells. Y190 cells were cotransfected with GAL4-DBD-
E6 and various GAL4-AD-p53 mutants (dark bars). Positive and negative controls are represented by grey bars. For other details see legend
to Fig. 2A.
in the binding ability of low risk HPV6 E6 and high risk it was shown by others that high risk genital E6 pro-
teins are able to interact with E6AP in vitro in the ab-HPV16 E6 to the carboxyterminal deletion mutant of p53
may reflect distinct properties between both E6 proteins sence of p53 (Huibregtse et al., 1991, 1993b), and in
this report we observed an interaction between theor simply results from the already lower affinity of HPV6
E6 to p53 in the yeast cells. To ensure a sufficient expres- nontransforming E6 protein of HPV6 with p53 although
it cannot bind to E6AP in vitro (Chen et al., 1995). Ifsion of all GAL4-AD-p53 and GAL4-DBD-E6 proteins in-
volved, Western blot analysis of cotransfectants were the interaction of E6AP with E6 proteins may also be
relevant with respect to transformation is to date un-performed, which revealed that all proteins were equally
stable in yeast cells (data not shown). known. To address this question for the cutaneous
transforming E6 proteins we investigated whether
GAL4-DBD-1 E6 and -8 E6 are able to interact withBinding of the E6 proteins to E6AP in the yeast two-
E6AP in the yeast system. As controls we used GAL4-hybrid system
DBD-6 E6 and 16 E6. To do so we fused the coding
It has been described that the E6-associated protein sequence of E6AP (Huibregtse et al., 1993a) to the
(E6AP) is necessary for the E6-mediated degradation activation domain of GAL4 and performed b-galactosi-
of p53 in reticulocyte lysates. The role of E6AP in the dase assays of cotransfected yeast cells, which con-
normal ubiquitin-dependent degradation of p53 in un- tained each of the GAL4-DBD-E6 fusion proteins. No
infected mammalian cells remains, however, unclear measurable interaction between the GAL4-DBD-E6
(Maki et al., 1996). In a recent report Chen et al. (1995) proteins of the cutaneous types 1 and 8 or of HPV6 E6
showed an interesting phenotype for the transforming and the GAL4-AD-E6AP protein could be detected (Fig.
E6 protein of BPV1. While BPV1 E6 did not bind to or 4). In contrast, GAL4-DBD-16 E6 interacted with GAL4-
AD-E6AP in cotransfected yeast cells, as measured bydegradated p53, however, it bound to E6AP. In addition
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FIG. 4. Interaction between HPV E6 proteins and E6AP in yeast cells. Y190 cells were cotransfected with GAL4-DBD-E6 and GAL4-AD-E6AP
(dark bars). Positive and negative controls are represented by grey bars. For other details see legend to Fig. 2A.
the activation of both reporter genes (Fig. 4). Therefore was observed in a concentration-dependent manner us-
ing the expression vector for HPV16 E6 (Fig. 5, rhombs).no correlation between E6AP binding and transforming
ability could be detected, whereas the property of HPV6 E6 was only able to repress p53 activity at high
intracellular concentrations (Fig. 5, squares), which couldHPV16 E6 to mediate p53 degradation was clearly a
function of E6AP binding. be a reflection of the lower binding affinity to p53 as we
observed in the yeast two-hybrid system. No effect on
Influence of E6 on p53-mediated transcriptional p53-mediated transactivation could be detected even at
activation high amounts of cotransfected expression vectors en-
coding HPV1 E6 or 8 E6 (Fig. 5, triangles and circles,Since it is known that the binding of E6 proteins to the
respectively). These results are colinear with our findingstumor suppressor protein mediates the downregulation
from the yeast two-hybrid system where no interactionof p53-dependent transcription of responsive promoters,
between the E6 proteins of the cutaneous HPV types 1we tested if the binding behavior of the GAL4-DBD-E6
and 8 and the tumor suppressor protein p53 could beproteins to GAL4-AD-p53 which we observed in yeast
detected.cells is reflected by p53 inactivation in human cells. We
transiently cotransfected cells of the human cervical car-
Investigation of in frame deletion mutants
cinoma cell line C33A with a constant amount of a CAT-
of HPV16 E6
reporter construct harboring 13 p53 binding sites up-
stream of the polyoma virus early promoter (PG13CAT The transforming E6 proteins of HPV1 and 8 neither
interact with p53 or E6AP nor do they have an influence(Kern et al., 1992)) and 10 ng of a p53 expression vector
(pC53SN3 (Baker et al., 1990)) together with increasing on the stability or sequence-specific DNA binding of the
p53 tumor suppressor protein. As a further step to eluci-amounts of the respective unfused E6 protein expression
vectors. Although C33A cells contain mutated p53 protein date if the oncogenic properties of E6 in rodent fibro-
blasts involve binding to p53, in frame deletions coveringit was shown that this did not interfere with the function
of transiently transfected p53 wild-type protein with re- the entire length of HPV16 E6 were generated. Because
it has been observed that mutations of cysteines in Cys-spect to its transactivating function (Crook et al., 1994;
Elbel, 1997). CAT activity was determined and expressed X-X-Cys-motifs resulted in protein instability, our strategy
was to delete short amino acid stretches within E6, butas the relative percentage of conversion rate (from [14C]
chloramphenicol to acetylated [14C]chloramphenicol) of to leave the conserved Cys-motifs intact. A map of five
independent in frame deletion mutants of HPV16 E6 isthe positive control HPV16 E6 in relation to the amounts
of cotransfected E6 expression vector (Fig. 5). A clear depicted in Fig. 6, upper panel, with the positions of the
deleted amino acids indicated. All mutants and wild-typeabrogation of p53-mediated transcriptional activation
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FIG. 5. Dose-dependent inhibition of p53-mediated transactivation by different E6 proteins. Cells were cotransfected with 1 mg reporter plasmid
(pG13CAT), 10 ng p53 expression vector (pC53SN3), and increasing amounts of expression vectors for HPV1 E6 (triangles), HPV8 E6 (circles), HPV6
E6 (squares), or HPV16 E6 (rhombs). CAT activity was determined with the help of a phosphoimager (Fuji) and expressed as the conversion rate
from nonacetylated to acetylated [14C]chloramphenicol. The amount of acetylated [14C]chloramphenicol produced by pC53SN3 without E6 was set
to 100%. Values represent the average of four independent experiments, with minimal duplicate transfections. Standard deviations are depicted as
black lines.
HPV16 E6 were cloned as fusion proteins with the hem- E6AP. The amount of b-galactosidase produced due to
the interaction of p53 or E6AP with the respective mutantagglutinin (HA) epitope at the C-terminus in the eukary-
otic expression vector pLXSN. First we transfected NIH E6 proteins is shown in Fig. 7, upper panel. Only the
deletion mutant 142/149 was still able to interact with3T3 cells with the individual mutant constructs and estab-
lished pools of G418-resistant cells which were tested the p53 tumor suppressor protein, which indicates that
the extreme C-terminal domain of HPV16 E6 is dispens-for anchorage-independent growth in softagar (Fig. 6,
lower panel). Although all five in frame deletions affected able for an association with p53. When we tested the
ability of the GAL4-DBD-16 E6 mutants to interact withthe transformation efficiency in comparison to wild-type
16 E6, the mutants 35/56 and 71/90 still led to a fair GAL4-AD-E6AP we received similar results. Besides the
wild type only mutant 142/149 was still able to interactnumber of colonies in the softagar assay. The N-terminal
deletion (18/25) and the deletion in the second zinc finger with GAL4-AD-E6AP; in general, however, the affinity of
the GAL4-DBD-16 E6 mutant to E6AP seems to be lower(108/126) and in the C-terminal domain (142/149) resulted
in a complete abolishment of the transforming potential than to p53.
To ensure that the lack of interaction between the fourof HPV16 E6. The number of colonies formed with these
mutants was not significantly different from the back- deletion mutants and p53 is not simply due to protein
instability, we performed Western blotting analysis whichground observed with pools established from HPV6 E6-
transfected cells. These data indicate that integrity of the revealed that all proteins are stably expressed in yeast
cells (data not shown).aminoterminal as well as the carboxyterminal domain,
including the second Cys-X-X-Cys-motif, is important to To next address the question whether the in frame
deletion mutants of HPV16 E6 can inhibit p53-mediatedmaintain the transforming function.
To establish a correlation between the transforming transcriptional activation, we transfected C33A cells with
10 mg of each of the E6 mutant pLXSN-constructs, to-properties of the mutant HPV16 E6 proteins and their p53
or E6AP binding abilities we expressed all mutants as gether with 1 mg of CAT reporter and 10 ng of p53 expres-
sion vector as described before (Fig. 7, lower panel). Infusion proteins with the DBD of GAL4 in yeast Y190 cells
cotransfected with human GAL4-AD-p53 or GAL4-AD- agreement with our data from the yeast two-hybrid sys-
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FIG. 6. In frame deletion mutants of HPV16 E6 and their interaction with p53. (A) Dark colored parts represent deleted portions of the HPV16 E6
protein. The first and the last deleted amino acid in each mutant construct is indicated. Encircled ‘‘C’’ represents conserved cysteine residues,
which form two zinc binding fingers (Zn). A hemagglutinin epitop (HA-tag) is fused to the last amino acid of all mutated and the wild-type HPV16
E6 protein. (B) Anchorage-independent growth of NIH 3T3 cells transfected with wild-type HPV16 E6-HA (wt 16 E6) or one of five individual in frame
deletion mutants of HPV16 E6. Softagar assays were carried out as described in the legend to Fig. 1. Negative control, NIH 3T3 cells were transfected
with HPV6 E6. Positive control, established cell line harboring HPV16 E6 (Schmitt et al., 1994).
tem only the in frame deletion mutant 142/149 inhibited labeled with [35S]cysteine and cellular extracts were di-
rectly immunoprecipitated with a HA-epitope-specific an-p53 transactivation to the same extent as wildtype 16 E6.
The other mutant E6 proteins 71/90 and 108/126 showed tibody in the presence of 2 mg anti-IgG antibody (Fig.
8A, lane 4, wild-type 16 E6, and lane 6, 142/149). Nono effect on p53, whereas 18/25 and 35/56 roughly re-
pressed p53-mediated transactivation by40%. To verify precipitation of E6 without additional anti-IgG antibody
was observed (Fig. 8A, lanes 3 and 5). As controls, mock-the expression of the important mutant 142/149 in mam-
malian cells, the E6 mutant 142/149 and wild-type 16 transfected cell extracts were incubated with anti-HA-
and anti-IgG-antibody (Fig. 8A, lane 2). Figure 8A, laneE6 were subcloned in an eukaryotic expression vector
allowing high levels of expression in cells containing the 1, shows an incubation of 16 E6-transfected cells with
an unrelated antibody. This analysis clearly showed thelarge T-antigen of SV40 (Mizushima and Nagata, 1990)
and transiently transfected into COS7. The cells were presence of detectable amounts of both E6 proteins in
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SDS–PAGE and the p53 proteins were visualized by fluo-
rography. With increasing amounts of ATPgS the ubiquiti-
nation of p53 becomes visible in the presence of wild-
type 16 E6 and 142/149. In a time course experiment we
observed a slower kinetic of mutant 142/149 in degrading
p53 as with wild-type 16 E6 (Fig. 8C). After 60 min 96%
of the input amount of p53 are degradated when wild-
type 16 E6 was present, whereas only 83% are degra-
FIG. 7. Interaction between wild-type p53 or E6AP and in frame
deletion mutants of HPV16 E6. (A) Y190 yeast cells were cotransfected
with GAL4-DBD-in frame deletion mutants of 16 E6 and GAL4-AD-p53
(dark bars) or GAL4-AD-E6AP (white bars). Controls, grey bars. For
other details see the legend to Fig. 2A. (B) Cells were transfected with
1 mg pG13CAT, 10 ng pC53SN3, and 10 mg of expression vectors for
wild-type HPV16 E6 or each in frame deletion mutant. The basal CAT
activity of pG13CAT (M) was set to ‘‘1.’’ Activities of the other constructs
are given as x-fold values relative to pG13CAT. Details on determination
FIG. 8. Expression of wild-type HPV16 E6 and 142/149 and degrada-of CAT activity are described in the legend to Fig. 5.
tion of p53. (A) Immunoprecipitation of wild-type 16 E6 and 142/149 in
COS7 cells. The E6 proteins were immunoprecipitated with a HA-spe-
cific antibody. The immunoprecipitation in lane 4 and 6 contained inthe transfected cells, although it cannot be ruled out that
addition 2 mg anti-IgG antibody allowing an efficient precipitation of wt
the mutant E6 protein may be functionally inactive due 16 E6 (lane 4) and 142/149 (lane 6). The E6 proteins are indicated by
to defective subcellular localization. an arrow. No precipitation occurred without anti-IgG antibody (lane 3
and 5). A reaction with an unrelated antibody (lane 1) and mock-trans-Since the transforming potential of HPV16 E6 mutants
fected COS7 cells (lane 2) served as negative controls. M, molecularin rodent fibroblasts does not correlate with the capacity
weight markers from top to bottom in kDa: 220, 97, 66, 46, 30, 19. (B)to directly bind to p53, we wanted to investigate whether
Ubiquitination of p53 in the presence of wild-type 16 E6 and 142/149.
the interaction between mutant 142/149 and p53 induces Ubiquitination reactions were performed in the presence of increasing
the ubiquitin-dependent degradation of the tumor sup- amounts of ATPgS as indicated. Details as described in the legend to
Fig. 1B. (C) Time course experiment of 142/149-induced degradationpressor protein in vitro. Thus p53 was translated in reticu-
of p53. p53 was incubated in the absence or in the presence of equallocyte lysate in the presence of [35S]methionine/cysteine
amounts of HPV16 E6, 18/25, or 142/149 at 257C as described underand incubated with wild-type 16 E6 or 142/149 at 257C
Material and Methods. 18/25 is depicted as a representative for all
(Fig. 8B). Increasing amounts of nonhydrolyzeable other in frame deletion mutants, which led to neither ubiquitination nor
ATPgS were added and the reactions were stopped after degradation of p53 in vitro (data not shown). Details on degradation
assay as described in the legend to Fig. 1C.60 min. The total reaction mixtures were analyzed on
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dated in the case of 142/149. All other mutants, which Comparatively little is known about the functions of
the E6 and E7 proteins of cutaneous papillomavirusesrevealed no binding to p53 in the yeast two-hybrid system
nor influenced the p53-mediated transcriptional activity that primarily infect the keratinizing skin outside of the
genital tract. In contrast to high risk genital types nowere also tested in the ubiquitination assay. Even in the
presence of high amounts of ATPgS no ubiquitinated immortalizing or transforming activities have been found
for the E7 proteins of the high risk types 8 and 47 (Iftnerforms of p53 appeared when 18/25, 35/56, 71/90, or 108/
126 were present in the reaction (data not shown). These et al., 1988; Schmitt et al., 1994; Hiraiwa et al., 1993). On
the other hand the ability of the E6 protein to transformresults reveal that binding of E6 to p53 and E6AP clearly
correlates with the ubiquitination and degradation of the established rodent fibroblasts seems to be a property
shared by genital and cutaneous types (Schmitt et al.,tumor suppressor protein but not with the transforming
potential of E6 in NIH 3T3 rodent fibroblasts. 1994; Iftner et al., 1988; Kiyono et al., 1992). The mecha-
nism of rodent cell transformation by the E6 protein, how-
ever, remains to be elucidated.DISCUSSION
In the case of the cutaneous HPVs almost nothing is
known about the interactions of the E6 proteins withA common necessity for all small DNA tumor viruses
is to induce DNA synthesis in quiescent cells to provide cellular ligands. One study only investigated the interac-
tion of in vitro-translated HPV8 E6 with murine p53cellular enzymes for the replication of the viral DNA. All
papillomaviruses investigated so far encode an E7 gene (Steger and Pfister, 1992), but did not check for degrada-
tion of p53 or interaction with E6AP. We therefore com-whose protein product interferes with the function of
members of the retinoblastoma family controlling the pared the properties of the cutaneous E6 proteins with
already known functions of E6 proteins of genital virusestransition from the G1-phase into the S-phase of the
cell cycle. Uncontrolled entry into S-phase, however, and found no correlation between p53-inactivation and
transforming potential neither for cutaneous nor for geni-activates negative growth control signals which have to
be bypassed by the virus to achieve production of prog- tal E6 proteins (summarized in Table 1).
When we tested the E6 protein of HPV1, 6, and 8 foreny viruses. Interestingly, while high risk genital HPV16
E7 is able to overcome different negative growth sig- interaction with p53 in reticulocyte lysates we observed
neither ubiquitination nor degradation of the p53 mole-nals, low risk HPV6 E7 does not exhibit such properties
(Demers et al., 1996). In addition to these remarkable cule, whereas HPV16 E6 efficiently degradated 96% of
the input amount of p53 protein within 1 h. This lack ofproperties of the E7 protein, high risk genital types en-
code an E6 protein that overcomes p53-mediated G1- function of the E6 proteins of HPV1, 6, and 8 to degradate
p53 correlated well with the inability of these E6 proteinsarrest and apoptosis in concert with the cellular E6AP
factor by targeting p53 for the enhanced ubiquitin-de- to interact with E6AP, as measured in the yeast two-
hybrid system.pendent degradation (Huibregtse and Scheffner, 1994).
Although many properties of the E6 and E7 proteins of It has been reported, however, that the nontrans-
forming HPV6 E6 in spite of having no influence on thehigh risk genital types have been discovered, the key
question, which of these functions is responsible for stability of p53 nevertheless can bind to the tumor sup-
pressor protein (Li and Coffino, 1996; Crook et al., 1991).the carcinogenic phenotype, is still discussed. One im-
portant difference between low and high risk genital This complex formation was shown to affect the se-
quence-specific DNA binding of p53, which is essentialtypes is the ability of the latter to immortalize primary
human keratinocytes (Halbert et al., 1992, 1991; Sedman for its transactivating function (Lechner and Laimins,
1994). Therefore the ability to form a complex with p53et al., 1992; Hawley-Nelson et al., 1989; Watanabe et
al., 1989; Mu¨nger et al., 1989). Second, the continuous seems to be a property shared by all genital types. To
investigate cutaneous E6 proteins for direct p53 bindingE6-mediated degradation of p53 may lead to an accu-
mulation of genetic mutations in the infected cell, which we used the yeast two-hybrid system, which allows mea-
surement of E6AP-independent complex formation be-clearly has to be regarded as an important contribution
to the carcinogenic action of high risk genital HPV types tween E6 and p53. In agreement with other studies, we
observed a strong binding of HPV16 E6 and a weaker(zur Hausen, 1994). In addition other cellular ligands,
like E6BP and paxillin, recently have been described binding of HPV6 E6 to human p53 expressed in yeast
cells. None of the cutaneous E6 proteins revealed a de-that bind specifically to the transforming E6 protein of
BPV1 and to the E6 protein of high risk genital types tectable interaction with p53. Transient transactivation
assays with a p53 reporter construct in a human epithe-but not to low risk types (Chen et al., 1995; Tong and
Howley, 1997). These newly identified interactions may lial cell line were in line with these findings from the
yeast two-hybrid system. Whereas HPV16 E6 had aalso contribute to the high risk phenotype either by alter-
ing the differentiation behavior of infected keratinocytes strong suppressive effect on p53-mediated transactiva-
tion, HPV6 E6 exhibited a minor influence only at highor by disrupting the actin cytoskeleton.
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TABLE 1
p53-Inactivation Does Not Correlate with Transforming Potential
p53-ubiquitination/ Inhibition of Transformation of
p53-binding p53-degradation p53-transactivation NIH3T3 fibroblasts
HPV1 E6 0 0 0 /
HPV8 E6 0 0 0 /
HPV6 E6 / 0 { 0
HPV16 E6 / / / /
mt 18/25 a 0 0 { 0
mt 35/56 a 0 0 { /
mt 71/90 a 0 0 0 /
mt 108/126 a 0 0 0 0
mt 142/149 a / / / 0
a In frame deletion mutants of HPV16 E6.
concentrations and the cutaneous E6 proteins were com- sequence-specific binding through an unoccupied core
domain. Removal of the carboxyterminal domain of p53,pletely inactive in this assay (Table 1).
It has been reported (Li and Coffino, 1996) that the p53 which had a modulatory effect on the stability of the
complex between 16 E6 and p53, may in the case of themolecule contains two binding sites for the E6 proteins,
one in the core region and another one at the carboxyter- weaker binding of HPV6 E6 simply cause reduction of
binding affinity below the level of detection.minus, but only E6AP-mediated binding to the core region
resulted in degradation of p53. To investigate if the com- Because we could not establish a correlation between
the transforming functions of the cutaneous E6 proteinsplex between E6 and p53 found under physiological con-
ditions in yeast cells depends on identical regions of the with any of the activities known from genital E6 proteins,
we next tested deletion mutants of the high risk HPV16p53 molecule we analyzed different mutants of p53. In
contrast to Li and Coffino (1996) we found no interaction E6 protein for their respective activities. For this, we con-
structed a number of in frame deletions of the HPV16 E6between E6 and the exactly same p53 core mutant (Cys-
135-Tyr). This may be explained by the different experi- gene and tested them for the ability to transform NIH
3T3 cells, bind p53 or E6AP, degradate p53, or inhibitmental conditions used; however, earlier reports using
the same in vitro techniques as Li and Coffino (1996) p53-mediated transactivation. A number of in vitro stud-
ies have already been performed to localize the domainswere also not able to demonstrate E6 binding to the
p53 (Cys-135-Tyr) core mutant (Scheffner et al., 1992; within the E6 molecule that are responsible for p53 bind-
ing or degradation; however, the results obtained wereHuibregtse et al., 1993a, 1991; Slebos et al., 1995). Taken
together with other existing data (Mansur et al., 1995) the somewhat controversial (Slebos et al., 1995; Foster et al.,
1994; Crook et al., 1991; Dalal et al., 1996; Nakagawa etcore region seems to be essential to mediate interaction
between E6 and p53 at least in the yeast two-hybrid al., 1995). Using the yeast two-hybrid system and other
techniques we now were clearly able to separate p53system. Interestingly, by using other p53 mutants with
deletions either at the amino- or carboxyterminal end we and E6AP binding from transforming activity. The HPV16
E6 mutant 142/149 with a deletion of eight amino acidsconfirmed in part the finding of Li and Coffino (1996)
that the carboxyterminus of p53 has an influence on the at the very end of the molecule was still able to bind
to p53 and E6AP, to degradate p53, and to inhibit itsstability of the p53–E6 complex. A deletion of the first
100 amino acids of p53 abolished the complex formation, transactivating function, but could no longer transform
NIH 3T3 cells. In contrast, two other deletion mutantswhereas deletion of the last 67 carboxyterminal amino
acids only reduced the binding affinity of HPV16 E6 to (35/56 and 71/90) efficiently induced softagar growth of
transfected NIH 3T3 cells, but were no longer able top53. In the case of HPV6 E6 the same carboxyterminal
deletion resulted in a complete loss of detectable interac- bind p53 or E6AP or degradate p53. These results are
partially in agreement with earlier experiments thattion with p53. Because binding of HPV6 E6 to p53 could
not be observed with the N-terminal and the core mutant showed that the carboxyterminus of HPV16/18 E6 is not
necessary for the interaction with p53 (Foster et al., 1994;of p53, one might conclude that these regions of the p53
protein are essential to mediate the weak interaction Pim et al., 1994). Interestingly the binding profile of the
E6 mutants to p53 and E6AP was the same and didwith HPV6 E6. The core binding also correlates with the
observed effect of HPV6 E6 to inhibit at high intracellular not support a possible role of E6AP interaction for the
transformation of rodent fibroblasts by E6. This indepen-levels the transactivation function of p53, which requires
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Cepko, C. L., Roberts, B. E., and Mulligan, R. C. (1984). Constructiondence of E6-mediated rodent cell transformation from
and applications of a highly transmissible murine retrovirus shuttlep53 or E6AP binding is, however, contrasted by the ne-
vector. Cell 37, 1055–1062.
cessity of p53 degradation in the immortalization of hu- Chen, J. J., Reid, C. E., Band, V., and Androphy, E. J. (1995). Interaction
man embryonic kidney cells (Nakagawa et al., 1995) or of papillomavirus E6 oncoproteins with a putative calcium-binding
protein. Science 269, 529–531.mammary epithelial cells (Dalal et al., 1996). Finally, we
Chiba, I., Takahashi, T., Nau, M. M., D’Amico, D., Curiel, D. T., Mitsu-could demonstrate that the carboxyterminus of HPV16
domi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, H., etE6 is important for the inherent transforming function of
al. (1990). Mutations in the p53 gene are frequent in primary, resected
the protein, which is in agreement with a study from non-small cell lung cancer. Lung Cancer Study Group. Oncogene 5,
Sherman and Schlegel (1996) showing that the carboxy- 1603–1610.
Coligan, J. E., Kruisbeek, A. D., Margulies, D. H., Shevach, E. M., andterminus of HPV16 E6 is required for the induction of
Strober, W. (1994). ‘‘Current Protocols in Immunology’’ (W. Strober,calcium and serum resistance of human keratinocytes
Ed.) Greene Publishing and Wiley-Interscience, New York.and for the immortalization in conjunction with E7.
Crook, T., Morgenstern, J. P., Crawford, L., and Banks, L. (1989). Contin-
In summary binding to p53 seems to be a prerequisite ued expression of HPV-16 E7 protein is required for maintenance of
for inhibition of p53-mediated transactivation but not to the transformed phenotype of cells co-transformed by HPV-16 plus
EJ-ras. EMBO J. 8, 513–519.be sufficient for degradation of p53, which is clearly a
Crook, T., Tidy, J. A., and Vousden, K. H. (1991). Degradation of p53 canfunction of E6AP. Both activities, however, are dispens-
be targeted by HPV E6 sequences distinct from those required forable for the transformation of rodent fibroblasts. Studies
p53 binding and trans-activation. Cell 67, 547–556.
are in progress to narrow down the domains in the E6 Crook, T., Fisher, C., Masterson, P. J., and Vousden, K. H. (1994). Modu-
protein which are responsible for rodent cell transforma- lation of transcriptional regulatory properties of p53 by HPV E6. Onco-
gene 9, 1225–1230.tion and to search for new cellular ligands of the E6
Dalal, S., Gao, Q., Androphy, E. J., and Band, V. (1996). Mutational analy-proteins with the aim to further elucidate the pathway of
sis of human papillomavirus type 16 E6 demonstrates that p53 degra-E6-mediated transformation.
dation is necessary for immortalization of mammary epithelial cells.
J. Virol. 70, 683–688.
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